SAVARA INC (SVRA) Stock Price & Overview

NASDAQ:SVRAUS8051111016

Current stock price

4.96 USD
-0.2 (-3.88%)
At close:
4.96 USD
0 (0%)
After Hours:

The current stock price of SVRA is 4.96 USD. Today SVRA is down by -3.88%. In the past month the price decreased by -10.31%. In the past year, price increased by 75.89%.

SVRA Key Statistics

52-Week Range1.89 - 7.005
Current SVRA stock price positioned within its 52-week range.
1-Month Range4.88 - 6.145
Current SVRA stock price positioned within its 1-month range.
Market Cap
1.009B
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.53
Dividend Yield
N/A

SVRA Stock Performance

Today
-3.88%
1 Week
-5.52%
1 Month
-10.31%
3 Months
-18.02%
Longer-term
6 Months +40.51%
1 Year +75.89%
2 Years -0.40%
3 Years +154.36%
5 Years +138.46%
10 Years N/A

SVRA Stock Chart

SAVARA INC / SVRA Daily stock chart

SVRA Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to SVRA. When comparing the yearly performance of all stocks, SVRA is one of the better performing stocks in the market, outperforming 88.06% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

SVRA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to SVRA. While SVRA seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SVRA Earnings

Next Earnings DateMar 26, 2026
Last Earnings DateNov 12, 2025
PeriodQ3 / 2025
EPS Reported-$0.14
Revenue Reported
EPS Surprise -3.49%
Revenue Surprise %

SVRA Forecast & Estimates

14 analysts have analysed SVRA and the average price target is 11.03 USD. This implies a price increase of 122.35% is expected in the next year compared to the current price of 4.96.


Analysts
Analysts85.71
Price Target11.03 (122.38%)
EPS Next Y-11.87%
Revenue Next YearN/A

SVRA Groups

Sector & Classification

SVRA Financial Highlights

Over the last trailing twelve months SVRA reported a non-GAAP Earnings per Share(EPS) of -0.53. The EPS decreased by -23.26% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-115.60M
Industry RankSector Rank
PM (TTM) N/A
ROA -82.03%
ROE -122.48%
Debt/Equity 0.32
Chartmill High Growth Momentum
EPS Q2Q%-27.27%
Sales Q2Q%N/A
EPS 1Y (TTM)-23.26%
Revenue 1Y (TTM)N/A

SVRA Ownership

Ownership
Inst Owners78.43%
Shares203.47M
Float187.64M
Ins Owners2.15%
Short Float %11.95%
Short Ratio14.99

About SVRA

Company Profile

SVRA logo image Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is headquartered in Langhorne, Pennsylvania and currently employs 59 full-time employees. The company went IPO on 2001-06-25. The firm is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The firm is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.

Company Info

IPO: 2001-06-25

SAVARA INC

1717 Langhorne Newtown Road, Suite 300

Langhorne PENNSYLVANIA 78746 US

CEO: Matthew Pauls

Employees: 59

SVRA Company Website

SVRA Investor Relations

Phone: 15126141848

SAVARA INC / SVRA FAQ

Can you describe the business of SAVARA INC?

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is headquartered in Langhorne, Pennsylvania and currently employs 59 full-time employees. The company went IPO on 2001-06-25. The firm is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The firm is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.


What is the current price of SVRA stock?

The current stock price of SVRA is 4.96 USD. The price decreased by -3.88% in the last trading session.


Does SVRA stock pay dividends?

SVRA does not pay a dividend.


How is the ChartMill rating for SAVARA INC?

SVRA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


On which exchange is SVRA stock listed?

SVRA stock is listed on the Nasdaq exchange.


Should I buy SVRA stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SVRA.


Who owns SAVARA INC?

You can find the ownership structure of SAVARA INC (SVRA) on the Ownership tab.